​
Anyone looking into Spero Therapeutics? Key indicators including test efficacy, regulatory reviews and financial investment - all seems promising.
​
**Clinical trial foundation and Regulatory:**
​
\- Overall success reached 58.5% for oral tebipenem HBr compared to 60.2% for the standard IV treatment and the drug was found to be statistically non-inferior to intravenous (IV).
​
\- In May 2025, an independent data monitoring committee recommended halting the trial early because tebipenem HBr rapidly and clearly met its primary efficacy goals.
​
\- The FDA granted the drug Fast Track and Qualified Infectious Disease Product (QIDP) status to speed up the review process.
​
\- The FDA review of tebipenem HBr is currently in its final days, with a highly anticipated Prescription Drug User Fee Act (PDUFA) target action decision date of June 18, 2026.
​
**Financials and Market:**
​
\- Pharma giant GSK took over the primary commercialisation and regulatory sponsorship duties from Spero Therapeutics, leading to the New Drug Application (NDA) resubmission in December 2025.
​
\- The filing triggered a $25 million milestone payment from GSK to Spero in early 2026, with Spero eligible for more than $300 million in future regulatory and sales milestones plus tiered royalties if approved.
​
\- **\*If\*** the FDA approves the application on **June 18 2026**, tebipenem HBr will officially become the **first** oral carbapenem antibiotic available to patients in the United States.
​
The \*if\* is key- would also be useful if SMEs in this domain can share typical success rates for trial 3? Of course a lot depends upon the type of medicine it is and other variables but a broad figure would help.
​